Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319

Benzinga · 3d ago
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $314 to $319.